REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients

REVERT’s Breakthrough in AI-Based Oncology Decision Support Featured in Open Access Government

The REVERT project has been recently featured in the prestigious Open Access Government digital publication. This recognition highlights the innovative work our consortium is doing to revolutionize treatment selection for patients with unresectable metastatic colorectal cancer (mCRC) through advanced AI-based decision support systems (DSS).

Open Access Government is a comprehensive digital publication that covers a wide range of topics related to public policy, research, technology, and innovation. It provides insights into government initiatives, academic research, and industry trends, making it an excellent platform for showcasing groundbreaking projects like REVERT.

The article featured in Open Access Government outlines REVERT’s unique approach to personalized medicine through AI. Our project brings together a consortium of 22 top-performing research centers, biobanks, clinical facilities, and four small to medium-sized enterprises (SMEs) from five European countries, all working collaboratively to advance cancer treatment. The AI-based DSS developed by REVERT aims to assist oncologists in selecting the most effective combinatorial treatments for mCRC patients by utilizing a consensus-driven approach across multiple AI centers.

What makes the REVERT DSS truly unique is its ability to generate a ranked list of treatment options for clinicians to consider. The system relies on a multi-party AI model, wherein four different AI centers independently develop classifiers to create the final DSS. These classifiers are trained on clinical data, biobank datasets, and real-world information to ensure a comprehensive and robust system. Clinicians can use the web-based interface to input patient data and receive personalized treatment recommendations, fostering a more individualized approach to cancer care.

The publication not only highlights the innovative aspects of the REVERT project but also underscores its commitment to explainable AI and the importance of clinician trust in AI-based systems. It emphasizes the role of multi-party, responsibility-sharing AI algorithms in enhancing the transparency and reliability of the decision support system.

We invite you to read the full article in Open Access Government to learn more about the REVERT project and our journey toward transforming cancer treatment through AI-driven personalized medicine.

You can read online the article by clicking on the following LINK and the entire April 2024 publication by clicking HERE.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848098”.

Copyright 2020 REVERT ©  All Rights Reserved